Bicara Therapeutics (NASDAQ:BCAX) Given “Outperform” Rating at Wedbush

Bicara Therapeutics (NASDAQ:BCAX)‘s stock had its “outperform” rating reaffirmed by analysts at Wedbush in a research report issued on Tuesday,Benzinga reports. They presently have a $30.00 target price on the stock. Wedbush’s target price suggests a potential upside of 57.32% from the stock’s current price.

BCAX has been the topic of a number of other research reports. HC Wainwright upped their price objective on shares of Bicara Therapeutics from $40.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday. Bank of America began coverage on Bicara Therapeutics in a research report on Wednesday, March 25th. They set a “buy” rating and a $35.00 price objective for the company. UBS Group reissued a “buy” rating on shares of Bicara Therapeutics in a research note on Wednesday, January 14th. Citigroup began coverage on Bicara Therapeutics in a research report on Thursday, January 29th. They issued an “outperform” rating for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Friday, January 9th. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $29.50.

Bicara Therapeutics Price Performance

BCAX stock traded up $0.03 during midday trading on Tuesday, hitting $19.07. The stock had a trading volume of 121,340 shares, compared to its average volume of 508,677. The business has a 50-day moving average of $17.15 and a two-hundred day moving average of $16.61. The firm has a market cap of $1.04 billion, a price-to-earnings ratio of -8.63 and a beta of -0.78. Bicara Therapeutics has a 52-week low of $7.80 and a 52-week high of $20.25.

Bicara Therapeutics (NASDAQ:BCAX) last announced its earnings results on Monday, March 30th. The company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.04. Research analysts predict that Bicara Therapeutics will post -2.59 earnings per share for the current year.

Insider Activity at Bicara Therapeutics

In other news, CEO Claire Mazumdar sold 1,596 shares of the stock in a transaction on Friday, March 20th. The stock was sold at an average price of $18.95, for a total transaction of $30,244.20. Following the transaction, the chief executive officer directly owned 339,392 shares of the company’s stock, valued at $6,431,478.40. This represents a 0.47% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Ryan Cohlhepp sold 12,500 shares of the firm’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $19.66, for a total value of $245,750.00. Following the completion of the transaction, the chief operating officer owned 200,641 shares in the company, valued at approximately $3,944,602.06. This trade represents a 5.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 137,969 shares of company stock valued at $2,586,198 in the last quarter.

Institutional Investors Weigh In On Bicara Therapeutics

A number of large investors have recently made changes to their positions in BCAX. AQR Capital Management LLC purchased a new stake in shares of Bicara Therapeutics during the 1st quarter valued at about $248,000. Woodline Partners LP increased its holdings in Bicara Therapeutics by 26.5% during the first quarter. Woodline Partners LP now owns 348,690 shares of the company’s stock valued at $4,543,000 after buying an additional 72,998 shares during the last quarter. Geode Capital Management LLC raised its position in Bicara Therapeutics by 36.8% in the second quarter. Geode Capital Management LLC now owns 672,485 shares of the company’s stock worth $6,248,000 after acquiring an additional 180,833 shares during the period. Intech Investment Management LLC boosted its stake in shares of Bicara Therapeutics by 65.3% during the 2nd quarter. Intech Investment Management LLC now owns 27,673 shares of the company’s stock worth $257,000 after acquiring an additional 10,927 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in shares of Bicara Therapeutics by 26.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 27,458 shares of the company’s stock worth $255,000 after acquiring an additional 5,664 shares during the last quarter.

Key Bicara Therapeutics News

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its price target from $40 to $42 and maintained a “buy” rating — a bullish analyst action implying ~120% upside from current levels. HC Wainwright Price Target Raise
• Positive Sentiment: Citizens Jmp reaffirmed a “market outperform” rating and set a $31 price target, signaling another analyst vote of confidence (~60% implied upside). Citizens Jmp Rating Reaffirmed
• Positive Sentiment: Company reported Q4 results that beat EPS estimates ($-0.68 vs. -$0.72) and provided a business update: selected 1,500 mg weekly as the Phase 3 dose for ficerafusp alfa, initiated the FORTIFI‑HN01 pivotal trial, and expects an interim analysis mid‑2027 — milestones that materially de‑risk the program. Bicara Q4 Results & Business Update
• Neutral Sentiment: Company commentary and call materials highlighted a strong cash position and program timelines (useful for financing runway but not an immediate price mover). Q4 Earnings Call Highlights
• Neutral Sentiment: Insider activity: CEO Claire Mazumdar sold 8,234 shares (~$154k) in early March, representing ~2.37% of her direct holdings — a modest insider sale that may raise questions for some investors but is small relative to her remaining stake. CEO Share Sale
• Neutral Sentiment: Full earnings call transcript is available for investors who want the management commentary and Q&A details. Earnings Call Transcript

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.